David Krige
Impact in
- Neurology top 2%
- Parkinson's Disease Mechanisms and Treatments
-
- Mitochondrial Function and Pathology
Papers in
-
- Multiple Myeloma Research and Treatments 4
- Acute Myeloid Leukemia Research 2
-
- Parkinson's Disease Mechanisms and Treatments 5
- Co-authors
- Anthony H.V. Schapira (6 shared papers)C. DAVID MARSDEN (4 shared papers)Vincent M. Mann (4 shared papers)S. E. Daniel (1 shared paper)Peter G. Jenner (1 shared paper)Alfredo Martı́nez (1 shared paper)Scott Cuthill (1 shared paper)Deborah H. Brotherton (1 shared paper)
- Journals
- Blood (2 papers)Oncotarget (2 papers)Journal for ImmunoTherapy of Cancer (2 papers)Annals of Oncology (2 papers)Cancer Research (2 papers)
- Partner nations
- United KingdomUnited StatesSpain
In The Last Decade
David Krige
25 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 67
- Neurology 518
- Molecular Biology 463
- Cancer Research 77
- Hematology 72
- Oncology 93
Countries citing papers authored by David Krige
This map shows the geographic impact of David Krige's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Krige with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Krige more than expected).
Fields of papers citing papers by David Krige
This network shows the impact of papers produced by David Krige. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Krige. The network helps show where David Krige may publish in the future.
Co-authors
The 25 scholars most cited alongside David Krige, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1992 | 323 | |
| 2 | 1992 | 308 | |
| 3 | 2011 | 108 | |
| 4 | 2008 | 104 | |
| 5 | 1992 | 90 | |
| 6 | 2011 | 61 | |
| 7 | 1994 | 59 | |
| 8 | 2009 | 46 | |
| 9 | 2021 | 44 | |
| 10 | 2004 | 41 | |
| 11 | 2012 | 36 | |
| 12 | 2023 | 36 | |
| 13 | 1992 | 32 | |
| 14 | 2015 | 30 | |
| 15 | 2010 | 18 | |
| 16 | PLATELET MITOCHONDRIAL-FUNCTION IN PARKINSONS-DISEASE | 1992 | 11 |
| 17 | 2013 | 11 | |
| 18 | Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector IMCgp100 in advanced uveal melanoma | 2017 | 7 |
| 19 | 2019 | 7 | |
| 20 | 1997 | 6 |
About David Krige
David Krige is a scholar working on Hematology, Neurology, Oncology, Cancer Research and Genetics, having authored 25 papers that have together received 1.4k indexed citations. Recurring topics across this work include Parkinson's Disease Mechanisms and Treatments (5 papers), Multiple Myeloma Research and Treatments (4 papers), Cancer Immunotherapy and Biomarkers (3 papers), Virus-based gene therapy research (3 papers), Acute Myeloid Leukemia Research (2 papers), Histone Deacetylase Inhibitors Research (2 papers), Mitochondrial Function and Pathology (2 papers) and Peptidase Inhibition and Analysis (2 papers). The work is most often cited by research in Neurology (518 citations), Molecular Biology (463 citations), Cancer Research (77 citations), Hematology (72 citations) and Oncology (93 citations). David Krige has collaborated with scholars based in United Kingdom, United States and Spain. Frequent co-authors include Anthony H.V. Schapira, C. DAVID MARSDEN, Vincent M. Mann, S. E. Daniel, Peter G. Jenner, Alfredo Martı́nez, Scott Cuthill, Deborah H. Brotherton, Marta Soler and P. R. J. Barnes. Their work appears in journals such as Blood, Oncotarget, Journal for ImmunoTherapy of Cancer, Annals of Oncology and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.